Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Oct

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Revumenib Approved by FDA for NPM1 AML

FDA Approves Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma

Metastatic ER-Positive HER2-Negative Breast Cancer Novel Treatment Combination Improves Progression-Free Survival

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC

Thymic Health Associated With ICI Response